Unknown

Dataset Information

0

Dapagliflozin: BMS 512148; BMS-512148.


ABSTRACT: Dapagliflozin, a selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2) is in development for type 2 diabetes mellitus with Bristol-Myers Squibb and AstraZeneca. It is currently undergoing phase III development worldwide with regulatory submissions expected in the second half of 2010. This review looks at the development history and scientific profile of this drug to date.

SUBMITTER:  

PROVIDER: S-EPMC3586122 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| PRJNA310024 | ENA
2019-12-16 | GSE98658 | GEO
| S-EPMC5676566 | biostudies-literature
| PRJNA243590 | ENA
| S-EPMC8416713 | biostudies-literature
| S-EPMC3393465 | biostudies-literature
| S-EPMC6064582 | biostudies-literature
2024-02-29 | GSE249860 | GEO
| S-EPMC3470910 | biostudies-literature
| S-EPMC3674329 | biostudies-literature